Benjamin Besse

发表

Integrated molecular portrait of non-small cell lung cancers

Pierre Validire, Philippe Dessen, Joakim Lundeberg, 2013, BMC Medical Genomics.

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

Pedro Mendez, Jose Luis Mate, Rafael Rosell, 2005, Lung cancer.

Whole brain radiotherapy in patients with NSCLC and brain metastases

B. Besse, F. Dhermain, Benjamin Besse, 2016, The Lancet.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Olivier Lantz, Laurence Zitvogel, Clotilde Théry, 2015, Oncoimmunology.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Susan Quinn, Revathi Ananthakrishnan, Thomas J Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities

Joakim Lundeberg, Henrik Gréen, Andrea Lindgren, 2015, Clinical Cancer Research.

The evolving role of histology in the management of advanced non-small-cell lung cancer.

E. Brambilla, J. Soria, C. Langer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Pierre Validire, Yudi Pawitan, Angel Porgador, 2015, Oncotarget.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Jordi Remon, J. Pignon, D. Planchard, 2017, Lung cancer.

Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology

Justin Guinney, Frederic Commo, Charles Ferté, 2013, Clinical Cancer Research.

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

Tae Min Kim, Bruce E. Johnson, Fabrice Barlesi, 2016 .

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

Bastien Cabarrou, Thomas Filleron, Juergen Wolf, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

Benjamin Solomon, A. Shaw, E. Felip, 2016 .